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Abstract

Go to:

Membranoproliferative GN represents a pattern of injury seen on light microscopy. Historically, findings
on electron microscopy have been used to further subclassify this pathologic entity. Recent advances in
understanding of the underlying pathobiology have led to a proposed classification scheme based on
immunofluorescence findings. Dysregulation of the complement system has been shown to be a major risk
factor for the development of a membranoproliferative GN pattern of injury on kidney biopsy. Evaluation
and treatment of this complex disorder rest on defining the underlying mechanisms.

Introduction
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Membranoproliferative GN (MPGN), also termed mesangiocapillary GN, accounts for approximately 7%–
10% of all cases of biopsy-confirmed GN (1,2). A light microscopic pattern of injury, MPGN occurs in
both children and adults. The presentation is usually slowly progressive disease with hematuria and nonnephrotic proteinuria, but nephrotic syndrome and more severe presentations have been described as well.
Among glomerular diseases, MPGN pathology has the most association with secondary causes, including
viruses, autoimmune diseases, and paraproteins (Table 1) (3).

Historical Classification
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The term MPGN refers to the features noted on light microscopy (LM). It is usually characterized by
mesangial hypercellularity, endocapillary proliferation, capillary wall remodeling, double contour
formation, and duplication of basement membranes (Figure 1). Traditionally, MPGN has been further
classified based on the findings of electron microscopy (EM) as primary MPGN type I (MPGN I), MPGN
II, MPGN III, or secondary MPGN. MPGN I, the most common form, is characterized by subendothelial
deposits, and MPGN III has both subepithelial and subendothelial deposits (4). MPGN II is characterized
by dense deposits in the glomerular basement membrane (dense deposit disease [DDD]).
The newer classification (5–7) of MPGN is dependent on immunofluorescence (IF) staining. This
pathophysiology-based classification is most useful to clinicians. Given recent advances in our
understanding of the role of the alternative pathway of complement in MPGN, a practical approach is to
view MPGN as either immune complex– or complement-mediated. Immune complex–mediated MPGN
may occur when there are increased levels of circulating immune complexes, and complement-mediated
MPGN may occur because of dysregulation of the alternative pathway of complement. If neither of these
causes is present (null complement and null immune complex), then chronic thrombotic microangiopathy
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC3944764/?report=printable
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may be the cause of the MPGN (Figure 2). The older classification gave a diagnosis but not much insight
into the pathophysiology of the disease (Table 2). Given the emergence of many secondary causes of
MPGN, it is hard to quantify the true incidence of idiopathic MPGN in both children and adults.

Immune Complex–Mediated MPGN
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Disease entities that are associated with MPGN are chronic or relapsing conditions, such as hepatitis B,
hepatitis C (8), autoimmune diseases (9,10), and monoclonal gammopathy of undetermined significance
(MGUS) (11). The immune complex form of MPGN is caused by deposition of immune complexes, which
results from paraproteinemias, autoimmune diseases, or chronic infections. Complement is activated
through the classic pathway, and on IF, there will be monoclonal or polyclonal Igs with complement
components. Table 1 reviews known causes of MPGN that result from the above three main categories.
MPGN has been noted with many autoimmune diseases (8). Although systemic lupus erythematosus may
be the most common cause, Sjogren’s syndrome (SS) and rheumatoid arthritis (RA) are other common
causes (9,10,12). Interestingly, a recent study from Mayo Clinic showed that the most common
autoimmune causes of MPGN were SS and RA (13). Chronic infections are known to cause MPGN (
Table 1). Hepatitis C and B are the most frequently described infections associated with MPGN (3,8), and
MPGN I associated with type II cryoglobulinemia is the most common form of kidney disease associated
with hepatitis C infection. Why only some patients develop kidney lesions has yet to be determined (8).
Kidney Disease Improving Global Outcomes (KDIGO) established guidelines for management of hepatitis
C-induced kidney diseases in 2008 (14). Given the high incidence of hepatitis C–associated glomerular
diseases, it is suggested that patients be tested at least annually for proteinuria, hematuria, and serum
creatinine.
Although prior reports had usually mentioned paraproteinemias as major causes of MPGN, recently, Sethi
et al. (11) described the important association of MGUS and MPGN. Traditionally, MGUS was thought to
be benign, although with some risk of progressing to multiple myeloma. However, it is now known that
MGUS, even without progression to myeloma, may cause kidney injury. Particular pathologic B cell or
plasma cell clones may be responsible and lead to an MPGN pattern of injury. Classically, all of these
cases had monoclonal deposition findings on kidney biopsy (IF). Some cases were associated with lowgrade B cell lymphoma, lymphoplasmacytic lymphoma, or chronic lymphocytic leukemia. Many studies
have suggested calling it monoclonal gammopathy of renal significance (15).

C3 Glomerulopathy: DDD and C3GN
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LM findings of MPGN, accompanied by C3 dominant staining on IF, point to dysregulation of the
alternative pathway (AP) of the complement system as the underlying defect, which distinguishes C3
glomerulopathy from the more common immune complex–mediated forms of glomerular diseases, such as
postinfectious GN. The term C3 glomerulopathy encompasses a spectrum of renal diseases highlighted by
AP dysregulation. In other words, the glomerular morphology as shown on LM is heterogeneous. To date,
the principal entities that represent C3 glomerulopathy are DDD, which is historically classified as MPGN
II, and C3GN (14). EM aids in differentiating between these disorders; mesangial deposits accompanied by
highly dense intramembranous deposits suggest a diagnosis of DDD (Figure 3), whereas the presence of
deposits in mesangial, subendothelial, subepithelial, and/or intramembranous locations suggests C3GN. Of
note, the composition of the deposits in C3 glomerulopathy is typically devoid of Ig and consists mainly of
complement proteins, particularly C3 and terminal complement components (C5b-C9) (16).
The complement system represents a primary defense modality. Its activation results in recruitment of
neutrophils and pathogen elimination by apoptosis and cell lysis. The complement system is activated
through three primary pathways—classic pathway, lectin pathway, and AP. The classic pathway and lectin
pathway are triggered by Igs and bacterial carbohydrates, respectively, whereas the AP maintains a
constant, spontaneous low level of activity with mechanisms that exist to maintain tight control, including
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC3944764/?report=printable
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activating and inhibitory proteins. Genetic mutations or acquired antibodies to these proteins result in
dysregulation of the complement system. It results in overdrive and ongoing amplification of the AP,
leading to potential organ damage (17).
Activation of the AP begins with cleavage of C3 by C3 convertase, resulting in formation of C3a and C3b.
Activators of the AP include factor B (FB) and factor D—both of which promote another generation of C3
convertase and lead to AP amplification (17,18).
C3b interacts with FB. This C3bFB complex then interacts with factor D and results in a complex of C3
convertase with C3bFB, which then promotes formation of C5 convertase; C5 convertase cleaves C5 into
C5a and C5b. C5a (along with C3a) acts as a chemoattractant, recruiting neutrophils and promoting an
inflammatory cascade. C5b leads to the final product of complement activation, C5b-C9 (otherwise known
as soluble membrane attack complex). The membrane attack complex leads to the formation of
transmembrane pores, resulting in osmotically-driven water entry, which causes cell lysis (17–19).
Inhibitors of the AP include factor H (FH) and its related proteins (FHRPs) factor I (FI), CD35, and
membrane cofactor protein (MCP; also known as CD46). FH is the principal inhibitor, and mutations in
FH or FHRP lead to significant AP dysregulation. Murine models support this pathobiology, because
genetically altered mice deficient in FH develop a renal injury pattern similar to DDD (20). Figure 4
illustrates the general schematic of the AP.
Depending on the environment, C3b, instead of interacting with FB, may be inactivated by FH and FI. FH
binds to C3b and is the primary cofactor for FI-induced lysis of C3b. It results in the formation of inactive
C3b, which can no longer participate in the formation of C3 convertase (18,19).
Properdin is a positive regulator of the AP and acts as a stabilizer of C3 convertase. In its absence, C3
convertase rapidly degrades, halting additional amplification of the AP. Deficiency of properdin is a risk
factor for infections with encapsulated organisms because of eventual lack of C5b-9. Recent experimental
studies of mice deficient in both FH and properdin surprisingly revealed increased C3 glomerular deposits
and inflammation (21).
C3 nephritic factor (C3Nef) is an autoantibody that stabilizes the activity of C3 convertase, making it
resistant to the degradation effects of FH, thereby increasing the half-life of C3 convertase and promoting
AP amplification. Approximately 80% of DDD patients are positive for C3Nef. However, C3Nef presence
has also been shown in ∼40% of C3GN patients, potentially nullifying its use as a specific marker for
DDD (7).
Although C3Nef is common in DDD, other processes leading to AP dysregulation and DDD have been
identified. Autoantibodies that bind to native FB and lead to stabilization of C3 convertase have been
described, and patients with stabilizing autoantibodies to both FB and C3b have also been described.
Blocking of FH activity by autoantibodies to FH has been shown in patients with DDD as well (22). DDD
has also been also associated with monoclonal gammopathy. As a result, it is possible that not all MGUS
patients have an immune complex–related MPGN pattern of injury in the kidney; some might have
dominant C3 only on IF (23).
In 2010, Martínez-Barricarte et al. (16) first described a C3 mutation in two patients with DDD from the
same family. The mutation made C3 resistant to cleavage by C3 convertase, consequently making the
formation of C3b impossible. However, the mutated C3 did get cleaved by proteases and spontaneous
hydrolysis, leading to formation of C3b and C3 convertase that were resistant to the breakdown efforts of
FH. This case showed that DDD in this family was attributable to dysregulation of AP and not the typical
mechanism of C3Nef/altered FH. It should be noted that the LM findings accompanying DDD are not
limited to MPGN and can include mesangial proliferative as well as crescentric patterns of injury.

https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC3944764/?report=printable
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As stated earlier, the term C3 glomerulopathy represents a heterogeneous group of disorders; although the
renal pathology is most commonly highlighted by MPGN on LM and C3 dominant deposits on IF, the
underlying pathobiology can be quite variable (24). Servais et al. (24) first described C3 glomerulopathy in
19 patients. The patients were divided into two groups—patients with C3 dominant staining on IF with
membranoproliferative features on LM (n=13) and patients with C3 dominant disease without mesangial
proliferation (n=6). Servais et al. (24) showed a wide spectrum of disease, which was characterized
combined or exclusively by mutations in FH, FI, MCP/CD46, and C3Nef. Of note, in those patients with
findings of MPGN, 5 of 13 patients were positive for C3Nef compared with 2 of 6 patients in the C3GN
group. Defects in complement regulatory proteins (primarily FH) were detected in 4 of 6 patients with
C3GN compared with only 2 of 13 patients with MPGN. Importantly, serum C3 levels were variable, and
the presence of a normal C3 did not preclude AP dysregulation (24).
Gale et al. (25) identified a gene mutation among two families from Cyprus that led to C3GN. A total of
26 patients were identified. The mutation results in defective co-FH–related protein 5 (CFHR5). Mutated
CFHR5 shows a decrease in complement interaction compared with the wild type, potentially leading to
AP dysregulation. A larger cohort of CFHR5 was identified by Athanasiou et al. (26). Expanding on the
original cohort described by Gale et al. (25), Athanasiou et al. (26) described 91 patients from 16 different
pedigrees. Approximately 30% of patients progressed with proteinuria/renal failure; 15% of patients
developed ESRD. Of note, approximately 70% of those patients who developed ESRD were men. LM may
show a mesangioproliferative or MPGN pattern of injury; on EM, there are typical subendothelial and
mesangial deposits with occasional subepithelial deposits. At this point, CFHR5 nephropathy seems
confined to those patients of Cypriot descent. All reported cases of CFHR5 to date have been negative for
C3Nef (26).
Sethi et al. (27) described 12 cases of C3 glomerulopathy with varying LM features (MPGN, mesangial
proliferative GN, and diffuse endocapillary GN) with isolated C3 deposits on IF. AP dysfunction was
because of a range of acquired and genetic conditions. C3Nef was again found to be the most common
acquired defect; FH allele polymorphisms were the most common genetic defect. FH autoantibodies, along
with mutations in FH, FI, and FHRP, were noted as well.
Recently, Tortajada et al. (28) reported a genetic mutation affecting CFHR1 and resulting in C3GN. A
single pedigree was studied with three members affected. Studies performed by Tortajada et al. (28)
indicate that this particular mutation results in a CFHR1, which competes with the ability of FH to regulate
the AP, leading to AP dysregulation and C3 deposition.
To further elucidate acquired and genetic abnormalities of the AP, Servais et al. (29) analyzed 134 patients
across a spectrum of DDD, C3GN, and MPGN I. Less than one half of the patients presented with a low
serum C3. Close to 50% of patients were C3Nef-positive, the majority of which were in the DDD category,
confirming previous studies. Mutations in FH and FI were identified in ∼20% of patients, one half of
whom were also C3Nef-positive. Unexpectedly, one half of the patients with MPGN I had evidence of AP
dysfunction.
Taken together, the above case series represents a wide spectrum of disease under a rather simplified
phenotype on renal biopsy. There is significant variability with regards to presentation and course of
disease. The efforts to further elucidate the disease state will likely require a multicenter approach given its
relatively low incidence. Table 3 summarizes all known mutations with C3 glomerulopathy. Although
C3GN has been mostly found to have mutations and genetic abnormalities, an association with monoclonal
gammopathy has been described as well (23).
MPGN III is similar to MPGN I, except that subepithelial deposits are noted as well as subendothelial
deposits. Based on the EM findings, MPGN III is further classified into two principal variants: the Strife
and Anders variant and the Burkholder variant, which have different patterns of electron dense deposits
and disorganization of the glomerular basement membrane (4). The majority of the cases that were
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC3944764/?report=printable
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diagnosed as MPGN III using the old classification are likely to be C3GN. Some of these cases were
complement-positive but Ig-negative by IF microscopy. Some of these cases have been attributed to
resolving postinfectious GN, even in the absence of a history of recent infection. In such cases, strong C3
staining and lack of significant Ig staining raise the possibility of C3GN. Consistent with this hypothesis,
abnormalities in the alternative complement pathway have been found in many of these patients (30–32).
In many cases of postinfectious GN, the glomerular disease persists in the absence of infection. This
disease is called atypical postinfectious GN. Recent studies suggest that this variant might represent
undiagnosed C3GN (32).

MPGN without Immune Complexes and Complement
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When pathology reveals no immune complex deposits and no specific IF staining but the light microscope
reveals an MPGN pattern of injury, thrombotic microangiopathy (TMA) is the most likely diagnosis.
Injury to the endothelial cell can lead to a similar pattern without complement activation. Rennke (3)
discussed this possibility as early as 1995 among secondary causes of MPGN. Table 4 lists all causes noted
to cause TMA and an MPGN pattern of injury (10). With regards to transplant glomerulopathy, IF findings
of null C3 and null Ig can aid in distinguishing from recurrent MPGN (33) (Table 4).

Recurrence Post-Transplantation
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Post-transplant recurrence of MPGN has been reported with variable rates, in part depending on the
underlying pathobiology. MPGN associated with monoclonal gammopathy seems to have an earlier
recurrence with a more aggressive course. Interestingly, recurrence of MPGN in renal allografts is
associated with the presence of crescents in the native kidneys as well as the allograft (34).
Given the lack of a proven beneficial therapeutic intervention, the aggressiveness of treatment should
match the aggressiveness of the disease process. One large study using the older classification of MPGN
looked at recurrence rates in 88 patients with MPGN I (35). The incidence of allograft loss at 10 years
because of recurrent MPGN I was 14.4% (95% confidence interval, 7.6% to 26.4%), which was similar to
the incidence of recurrent FSGS. In an analysis of nearly 190,000 renal transplant patients in the United
Network for Organ Sharing database, the incidence of allograft loss at 10 years because of recurrent
MPGN I was similarly 14.5%, which was higher than other glomerulonephritides combined (36). We must
keep in mind that the histologic changes seen on transplant glomerulopathy have the MPGN pattern of
injury, and many of the recurrence rates might be overestimated. Nevertheless, findings on EM (such as
the absence of immune complex deposition in transplant glomerulopathy) may help distinguish between
these two disorders (33).
With regards to C3 glomerulopathy, DDD recurrence is the norm, with a 50% graft failure rate; data
regarding C3GN recurrence is limited, but recurrence has been reported (24,37,38). Ten patients with
CFHR5 nephropathy are reported with successful kidney transplantation (26), and one other patient with
disease recurrence after unrelated donor transplantation had successful kidney transplantation (39).

Evaluation of MPGN
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The evaluation of MPGN usually begins with recognition of the clinical syndrome of GN, which leads to a
kidney biopsy. In some cases, biopsy may be performed for other reasons, with MPGN being a surprise
diagnosis. In either case, the pathologic diagnosis of MPGN leads to a defined diagnostic pathway driven
by immunoflourescent pathology findings (Figure 2).
When renal pathology IF shows Igs and C3 (Ig+C3+), then, as discussed above, MPGN is considered to be
immune complex–mediated. In these cases, a careful evaluation for infection is warranted. Specifically,
serologies for evidence of infection with hepatitis B or C should be obtained. Evaluation for other
infections should be based on a clinical constellation of suggestive findings. Another cause of immune
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC3944764/?report=printable
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complex–mediated MPGN is the presence of a monoclonal gammopathy. Of patients with MPGN without
hepatitis B or C, 41% of patients have a monoclonal gammopathy of uncertain significance (11). Testing
could include serum free monoclonal light chain analysis, immunofixation, and serum and urine protein
electrophoresis. An additional cause of MPGN that is immune complex–mediated is SS. SS should be
suspected if typical signs and symptoms are present.
The greatest advances in MPGN have been in the area of complement-mediated disease. As discussed
above, when renal pathology shows predominant staining for C3, a C3 glomerulopathy is present.
Pathologic features help to further define the disease as DDD or C3GN (40). With these findings, serologic
testing of complement components should be performed with attention to activation of the alternative
pathway. Most patients will have persistently low levels of C3 and may be positive for C3 nephritic factor
(40). Ideally, testing to characterize the abnormalities leading to dysregulation of complement metabolism
should be performed. Such testing is currently available only at select research laboratories. Tests of
interest (Table 3) would include evaluation for antibodies associated with dysregulation of the alternative
complement pathway, including C3Nef, anti–co-FB autoantibodies, anti-FH, and anti-FI. Genetic testing
for key complement regulators, primarily co-FH, co-FI, MCP (CD46), and FH-related proteins, would be
helpful if available (40).

Treatment

Go to:

A review of the literature on the treatment of MPGN can be confusing, in that most published studies were
conducted before current knowledge on the different causes of disease. As a result, it should be advised
that earlier studies should probably not be considered when deciding on treatment for patients, because the
study cohorts were an admixture of patients with different pathobiologic conditions. After evaluation,
more targeted therapies based on current knowledge should be considered if a cause is identified (for
example, hepatitis C). Otherwise, immunosuppressive therapy may often be required. In general, it might
be said that treatment for MPGN syndromes, in general, is not well established.
The treatment of TMA-associated MPGN is to treat the underlying cause of the TMA, and it will not be
discussed in this review. Therapy for Ig+C3+ forms of MPGN are varied and directed by the underlying
pathobiology. Immune complex–mediated MPGN caused by SS, RA, and other rheumatologic diseases
should prompt a rheumatology-driven treatment plan with immunosuppressive agents. Treatment of
underlying chronic infection is required for MPGN associated with infections. Patients with MGUS and
MPGN are probably the most difficult to treat, because there is a paucity of evidence-based medicine to
guide therapy. These patients, however, likely have a very small clone of plasma cells producing offending
Ig and may respond to novel myeloma based therapies. Treating the underlying clone of cells might be the
solution (15). As per KDIGO recommendations from 2008, patients with acute flares of hepatitis C–
associated cryoglobulinemia and MPGN should be treated with immunosuppressive drugs (steroids,
cyclophosphamide, or rituximab), plasma exchange, and antiviral therapy. It is recommended that antiviral
therapy with standard IFN or pegylated IFN plus ribavirin be given for at least 12 months. Patients with
noncryoglobulinemic MPGN may be treated with standard IFN, pegylated IFN, or IFN plus ribavirin.
Relapses of systemic cryoglobulinemia and MPGN may be treated with increment doses of rituximab.
Patients with hepatitis C–associated glomerulopathy should receive therapy with antiproteinuric agents,
such as angiotensin-converting enzyme inhibitors and/or ARBs, to reduce proteinuria and antihypertensive
treatment to achieve target BP goals established for patients with CKD (14). Finally, for patients with
MPGN and an Ig+C3+ IF pattern, in whom the evaluation has not determined a cause (idiopathic disease),
treatment remains unclear. For less severe disease, conservative treatment aimed at BP control and
proteinuria management with careful observation may be appropriate. For severe disease,
immunosuppressive therapy is indicated. Although prednisone and cyclophosphamide may have grade 2C
evidence for use in MPGN, those trials were done in an era preceding the novel classification (41).

https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC3944764/?report=printable
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Nevertheless, treatment of rapidly progressive crescentic variant of the disease would favor using of
cytotoxic agents earlier than later. A full discussion of this subject is beyond the scope of this article.
Discussion here on will focus on the recent evolution of treatment for the C3 dominant variant of MPGN
or C3 glomerulopathy. The current literature of published studies on C3 dominant MPGN patients is
scarce. Conservative therapy may be effective, but stabilization has also been found for various immunemodulating agents (26). In a family described by Habbig et al. (42), repletion of FH was effective. The two
sisters described had a single deletion in the FH gene. There is currently no method for direct replacement
of FH; instead, plasma exchange is required. The group described by Habbig et al. (42) was treated with
fresh frozen plasma infusion for 36 months. This treatment will not be effective in all such patients
because of the diversity of pathogenesis, which was shown by Martínez-Barricarte et al. (16). In the family
described by Martínez-Barricarte et al. (16), a mutation in C3 convertase caused functional resistance to
FH; replacement would not have been effective.
An advance has been the development of eculizimab for treatment of this disease and related diseases. This
agent is a humanized monoclonal antibody that binds with great affinity to C5 proteins, inhibiting cleaving
into C5a and C5b and blocking production of the C5b-9 membrane attack complex. Reports of individual
cases showed that Ig−C3+ MPGN improved after treatment, with reduced serum creatinine and proteinuria
(43–46). In an illustrative case, a 16-year-old girl with renal biopsy indicated MPGN and low C3 levels;
plasma complement FH-related protein 1 was absent by immunoblotting. This finding suggested that
plasma exchange could be effective, which is discussed above; however, in this case, anuria persisted,
despite treatment. Treatment with eculizimab was initiated with dramatic results. Renal function
normalized rapidly (43). In a series of six patients with DDD or C3GN, Bomback et al. (47) found
eculizimab to result in either clinical or pathologic benefits in four subjects. Taken together, the early
results with eculizimab in this disease are promising, but additional studies will be necessary, because the
current literature is insufficient to assess the spectrum of benefit and risk of this agent. Herlitz et al. (48)
reported that, after 1 year of therapy with eculizumab, there was reduction in active glomerular
proliferation and neutrophil infiltration in three of five patients, consistent with effective C5 blockade,
which prevents production of chemotactin C5a. Interestingly, all post-treatment biopsies showed de novo
monoclonal staining for IgG-κ in the same distribution as C3 and C5b-9, mimicking monoclonal Ig
deposition disease. Staining of the γ-heavy chain was restricted to the IgG2 and IgG4 subclasses,
suggesting the binding of monoclonal eculizumab to C5 in renal tissues (48). The clinical relevance of this
finding is unclear at this point.
In summary, MPGN is a pattern of disease that has undergone significant reclassification, leading to
emergence of a new entity called C3 glomerulopathy. Nephrologists and pathologists should be aware of
these recent changes, because there are novel clinical implications for the treatment for DDD and C3GN.
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Table 1.
Immune complex-based conditions associated with membranoproliferative GN pattern of injury

Autoimmune diseases
Systemic lupus
Sjogren’s syndrome
Rheumatoid arthritis
Mixed connective tissue disease
Infections
Hepatitis B
Hepatitis C
Endocarditis
Shunt infections
Visceral abscesses
Leprosy
Malaria
Schistosomiasis
Mycoplasma

a
Paraproteinemias
Monoclonal gammopathy of undetermined significance
Waldenstrom macroglobulemia
Chronic lymphocytic leukemia
Low-grade B-cell lymphoma
Cyroglobulinemia types 1 and 2
Immunotactoid glomerulopathy
Monoclonal Ig deposition disease
Fibrillary glomerulopathy

a

Some paraproteins (e.g., monoclonal globulins type I) can aggregate spontaneously and form nonimmune deposits
(nonantigen–antibody complexes) in glomeruli.
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Figure 1.

Membranoproliferative GN (MPGN). Light microscopy hematoxylin & eosin stain. Reprinted from Glen Markowitz,
with permission.
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Figure 2.

Simplistic breakdown of the new MPGN classification using immunofluorescence as the basis and an approach to
evaluation when the kidney biopsy indicated MPGN. DDD, dense deposit disease; IF, immunofluorescence; SPEP,
serum protein electrophoresis; TMA, thrombotic microangiopathy; UPEP, urine protein electrophoresis.
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Table 2.
Older and newer classification of membranoproliferative GN
Based on Electron Microscopy (Older)
Classification MPGN 1: Subendothelial MPGN

Based on Immunofluorescence (Newer)
Immune complex–mediated MPGN Igs and
complements on IF (paraproteins, viruses,
autoimmune)

MPGN 2: Dense subendothelial deposits (dense

Complement-mediated MPGN C3 dominant IF

deposit disease)

(C3 glomerulopathy)

MPGN 3: Subendothelial

MPGN not related to complement or immune

membranoproliferative with intramembranous

complex

and subepithelial deposits
Negative IF (thrombotic microangiopathy)

IF, immunofluorescence; MPGN, membranoproliferative GN.

https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC3944764/?report=printable

15/19

7/5/2018

Update on Membranoproliferative GN

Figure 3.

Dense deposit disease electron microscopy. Reprinted from Glen Markowitz, with permission.
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Figure 4.

Alternate pathway (AP) schematic. Activation of the AP begins with C3 interacting with C3 convertase. C3 convertase
is activated or inhibited by a variety of factors and proteins. C3b and C3 convertase promote formation of C5 convertase.
C5 convertase, acting on C5, results in formation of C5a and C5b. C3a and C5a attract neutrophils. C5b interacts with
C6–C9 to form membrane attack complex.
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Table 3.
Known mutations/causes associated with C3GN

Autoantibodies to C3 convertase
Autoantibodies to factor H
Autoantibodies to factor B
Properdin deficiency
C3 nephretic factor
Complement factor H mutation screening identified the H402 allele and V62 allele
Heterozygous mutations in factor I gene
Heterozygous mutation in CD 46 gene (membrane cofactor protein)
Mutation in the gene for complement factor H-related protein 5
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Table 4.
Thrombotic microangiopathies associated with MPGN pattern of injury

Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (resolving)
Antiphospholipid syndrome
Radiation nephropathy (bone marrow transplant-related nephropathy)
Sickle cell disease
Transplant glomerulopathy
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